Full Press Release Details
Bicycle Therapeutics Announces Significant Progress
Across Multiple Therapeutic Programs Beyond Oncology
milestone achieved in neuroscience collaboration with Dementia Discovery Fund and the Alzheimer's Research UK Oxford Drug Discovery
advances made in the application of Bicycle technology against emerging antimicrobial and antiviral targets
Bicycles identified through multiple development partnerships
CAMBRIDGE, England, & BOSTON, March 30, 2021
- Bicycle Therapeutics plc (NASDAQ: BCYC), a biotechnology company pioneering a new and differentiated class of therapeutics
based on its proprietary bicyclic peptide (Bicycle ) technology, today announced
progress updates for its Bicycle-based partnered programs outside of oncology.
"Over the last five years, Bicycle's strategy has been
to use our novel technology to discover and develop a pipeline of innovative assets in oncology while additionally using non-dilutive
funding and collaborations to explore the therapeutic potential of Bicycles in disease areas outside of oncology. Today, for the
first time, we are providing an overview on our progress in demonstrating the broad utility of this platform to create molecules with
the potential to treat some of the most serious diseases and address future healthcare challenges," said Kevin Lee, Ph.D., Chief
Executive Officer of Bicycle Therapeutics. "It's incredibly exciting to see how the Company has worked innovatively and highly
collaboratively with many diverse institutions to address these challenges and, at the same time, generated significant revenues to offset
the costs of developing and progressing our internal oncology pipeline. I would like to thank all of our collaborators for their enthusiasm
in this endeavor and look forward to continuing our work to advance these important molecules."
Bicycle has achieved the first milestone in its collaboration
with Dementia Discovery Fund (DDF) and the University of Oxford's ARUK Oxford Drug Discovery Institute (ODDI)
Bicycle advances platform in multiple anti-infective areas, including
antimicrobials and antivirals
Bicycle has made significant progress through partnerships with
biopharmaceutical therapeutic area leaders in indications outside of oncology
commented, "With four Bicycle molecules now in clinical trials for both oncology and non-oncology indications, the
technology has shown initial evidence of clinical tolerability and suitability for pharmaceutical development, and I look forward to seeing
how Bicycles may bring important new treatment opportunities to poorly served patients in additional therapeutic areas."
About Bicycle Therapeutics
Bicycle Therapeutics (NASDAQ: BCYC) is a clinical-stage biopharmaceutical
company developing a novel class of medicines, referred to as Bicycles, for diseases that are underserved by existing therapeutics.
Bicycles are fully synthetic short peptides constrained with small molecule scaffolds to form two loops that stabilize their structural
geometry. This constraint facilitates target binding with high affinity and selectivity, making Bicycles attractive candidates
for drug development. Bicycle's lead product candidate, BT1718, a Bicycle Toxin Conjugate (BTC) that targets MT1-MMP, is
being investigated in an ongoing Phase I/IIa clinical trial in collaboration with the Centre for Drug Development of Cancer Research
UK. Bicycle is also evaluating BT5528, a second-generation BTC targeting EphA2, in a company-sponsored Phase I/II trial. BT8009 is a
BTC targeting Nectin-4, a well-validated tumor antigen, and is also currently being evaluated in a Company-sponsored Phase I/II trial.
Bicycle is headquartered in Cambridge, UK with many key functions and members of its leadership team located in Lexington, MA. For more
information, visit bicycletherapeutics.com.
Forward-Looking Statements
release may contain forward-looking statements made pursuant to the safe harbor provisions of the Private Securities Litigation Reform
Act of 1995. These statements may be identified by words such as "aims," "anticipates," "believes,"
"could," "estimates," "expects," "forecasts," "goal," "intends,"
"may," "plans," "possible," "potential," "seeks," "will" and variations
of these words or similar expressions that are intended to identify forward-looking statements, although not all forward-looking
statements contain these words. Forward-looking statements in this press release
include, but are not limited to, statements regarding anticipated advancement of preclinical development efforts and initiation of clinical
trials; the availability of data from preclinical studies and clinical trials; Bicycle's ability to generate shareholder value;
the therapeutic potential of Bicycle's and its collaborators' pre-clinical targets and product candidates; Bicycle's
and its' collaborators' ability to achieve planned milestones; and the availability of future funding. Bicycle may
not actually achieve the plans, intentions or expectations disclosed in these forward-looking statements, and you should not place undue
reliance on these forward-looking statements. Actual results or events could differ materially from the plans, intentions and expectations
disclosed in these forward-looking statements as a result of various factors, including: risks to Bicycle's and its collaboration
partners' abilities to meet anticipated deadlines and milestones presented by the ongoing COVID-19 pandemic; uncertainties inherent
in the initiation and completion of preclinical studies and clinical trials and clinical development of Bicycle's product candidates
by Bicycle or its collaboration partners; the risk that Bicycle or its collaboration partners may not realize the intended benefits of
Bicycle's technology; availability and timing of results from preclinical studies and clinical trials; whether the outcomes of preclinical
studies will be predictive of clinical trial results; whether initial or interim results from a clinical trial will be predictive of the
final results of the trial or the results of future trials; the risk that studies and trials may be delayed and may not have satisfactory
outcomes; potential adverse effects arising from the testing or use of Bicycle's product candidates; risks related to Bicycle's
ability to maintain existing collaborations and realize the benefits thereof; expectations for regulatory approvals to conduct trials
or to market products; and other important factors, any of which could cause our actual results to differ from those contained in the
forward-looking statements, are described in greater detail in the section entitled "Risk Factors" in our Annual Report on
Form 10-K filed with the Securities and Exchange Commission (SEC) on March 11, 2021, as well as in other filings Bicycle may
make with the SEC in the future. Any forward-looking statements contained in this press release speak only as of the date hereof, and
Bicycle expressly disclaims any obligation to update any forward-looking statements contained herein, whether as a result of any new information,
future events, changed circumstances or otherwise, except as otherwise required by law.
Investor and Media Contact: